Although most cancer cases are still pathologically confirmed novel techniques including cytogenetics and molecular diagnostics are increasingly used. Besides, many targeted therapies for specific molecular aberrations in cancer have been developed and many cancer patients nowadays receive these new drugs. In a webinar the new diagnostics will be explained in relation to coding the appropriate ICD-O morphology code. The different new drug categories, how they work and how they should be registered will also be explained.
The webinar was on the 6th April 2022.
Cancer registrars, statisticians and epidemiologists working in the European Cancer Registries.
The presentation is available here.